UY28289A1 - Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 y su uso para diasnostico y tratamiento de tumores - Google Patents

Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 y su uso para diasnostico y tratamiento de tumores

Info

Publication number
UY28289A1
UY28289A1 UY28289A UY28289A UY28289A1 UY 28289 A1 UY28289 A1 UY 28289A1 UY 28289 A UY28289 A UY 28289A UY 28289 A UY28289 A UY 28289A UY 28289 A1 UY28289 A1 UY 28289A1
Authority
UY
Uruguay
Prior art keywords
glycolyl
glicolil
diasnostic
recombinant antibodies
ganglioside
Prior art date
Application number
UY28289A
Other languages
English (en)
Inventor
Rodriguez Gonzalez Mabel
Roque Navarro Lourdes Tatiana
Mateo De Acostadel Rio C Maria
Rojas Dorantes Gertrudis
Talavera Perez Ariel
Moreno Frias Ernesto
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of UY28289A1 publication Critical patent/UY28289A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención se relaciona fundamentalmente con la producción de inmunoglobulinas menos inmunogénicas por la vía de la ingeniería genética, y más especialmente con un anticuerpo monoclonal que reconoce antígenos que contienen el gangliósido N-glicolil GM3 y no otros gangliósidos del tipo N-glicolil o N-acetil, ni a los glicolípidos sulfatados. Mas específicamente la presente invención se relaciona con las secuencias peptídicas que codifican un anticuerpo monocional recombinante contra el ganliósido n-glicolil GM3, o fraqgmentos derivados del mismo y composiciones farmacéuticas conteniendo dicho anticuerpo o sus fragmentos y sus tanto diagnostico o terapéutico en cáncer de mama y malanoma.
UY28289A 2003-04-23 2004-04-23 Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 y su uso para diasnostico y tratamiento de tumores UY28289A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20030092A CU23403A1 (es) 2003-04-23 2003-04-23 Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores

Publications (1)

Publication Number Publication Date
UY28289A1 true UY28289A1 (es) 2004-11-30

Family

ID=40261249

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28289A UY28289A1 (es) 2003-04-23 2004-04-23 Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 y su uso para diasnostico y tratamiento de tumores

Country Status (32)

Country Link
EP (1) EP1623997B1 (es)
JP (1) JP2006524194A (es)
KR (1) KR20060006937A (es)
CN (2) CN1809592A (es)
AR (1) AR044076A1 (es)
AU (1) AU2004232391B2 (es)
BR (1) BRPI0409664A (es)
CA (1) CA2523449C (es)
CL (1) CL2004000843A1 (es)
CR (1) CR8105A (es)
CU (1) CU23403A1 (es)
EA (1) EA008353B1 (es)
ES (1) ES2535813T3 (es)
GE (1) GEP20084476B (es)
HK (1) HK1183492A1 (es)
HR (1) HRP20050922A2 (es)
HU (1) HUE025266T2 (es)
IL (1) IL171541A (es)
LT (1) LT5353B (es)
LV (1) LV13427B (es)
MX (1) MXPA05011368A (es)
MY (1) MY144620A (es)
NZ (1) NZ543345A (es)
PE (1) PE20050422A1 (es)
PL (1) PL1623997T3 (es)
RS (2) RS20110319A3 (es)
SI (1) SI1623997T1 (es)
TN (1) TNSN05274A1 (es)
TW (1) TWI343923B (es)
UY (1) UY28289A1 (es)
WO (1) WO2004094477A1 (es)
ZA (1) ZA200509457B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69942782D1 (de) 1998-11-27 2010-10-28 Ucb Sa Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AU2011250920B2 (en) 2010-05-14 2015-05-21 Amgen Inc. High concentration antibody formulations
EP2681242B1 (en) 2011-03-01 2018-01-24 Amgen Inc. Sclerostin and dkk-1 bispecific binding agents
PE20140437A1 (es) 2011-03-25 2014-04-17 Amgen Inc Formulaciones de anticuerpos
HUE039786T2 (hu) 2011-08-04 2019-02-28 Amgen Inc Csonthiány-defektusok kezelési módszere
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP2797953B1 (en) 2011-12-28 2020-06-03 Amgen Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
CU24120B1 (es) * 2012-03-01 2015-08-27 Ct De Inmunología Molecular Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3
JP6770312B2 (ja) 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム 骨疾患の治療
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
CN104651314B (zh) * 2015-02-14 2018-06-19 百泰生物药业有限公司 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
AU2016382512A1 (en) 2015-12-30 2018-07-12 Novartis Ag Immune effector cell therapies with enhanced efficacy
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
CN111566124A (zh) 2017-10-25 2020-08-21 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras
WO2019191534A1 (en) 2018-03-30 2019-10-03 Amgen Inc. C-terminal antibody variants
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
KR102344948B1 (ko) * 2018-09-03 2021-12-28 세종대학교산학협력단 인간 순수만능줄기세포에 특이적인 단일클론항체 n1-a4
CN113271945A (zh) 2018-12-20 2021-08-17 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN110208409A (zh) * 2019-06-05 2019-09-06 中国海洋大学 一种乳腺癌的生物标志物及其应用
CA3165399A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021123908A1 (en) 2019-12-20 2021-06-24 Ludwig Institute For Cancer Research Ltd Car-t cell therapy targeting ngcgm3

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
EP1759709B1 (en) * 1994-01-25 2013-02-27 Elan Pharmaceuticals Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CA2203236A1 (en) 1994-10-28 1996-05-09 Ira Pastan Tumor-specific antibody fragments, fusion proteins, and uses thereof
NZ311174A (en) * 1995-06-30 1999-04-29 Mochida Pharm Co Ltd Anti-fas ligand antibody which suppresses fas ligand-induced apoptosis in cells and method of assaying a fas ligand using the anti-fas ligand antibody
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen

Also Published As

Publication number Publication date
RS20110319A2 (en) 2012-02-29
CN103012586B (zh) 2014-08-06
BRPI0409664A (pt) 2006-04-18
LT5353B (lt) 2006-07-25
CA2523449A1 (en) 2004-11-04
TWI343923B (en) 2011-06-21
EA008353B1 (ru) 2007-04-27
MXPA05011368A (es) 2006-03-08
RS20110319A3 (en) 2012-10-31
CU23403A1 (es) 2009-08-04
CN103012586A (zh) 2013-04-03
CR8105A (es) 2006-05-31
HUE025266T2 (en) 2016-02-29
IL171541A (en) 2013-11-28
CA2523449C (en) 2012-09-18
LV13427B (en) 2006-09-20
RS20050795A (en) 2007-12-31
LT2005101A (en) 2006-03-27
SI1623997T1 (sl) 2015-07-31
WO2004094477A1 (es) 2004-11-04
JP2006524194A (ja) 2006-10-26
EP1623997A1 (en) 2006-02-08
EA200501653A1 (ru) 2006-06-30
PL1623997T3 (pl) 2015-08-31
HRP20050922A2 (en) 2007-03-31
TNSN05274A1 (en) 2007-07-10
ZA200509457B (en) 2006-07-26
MY144620A (en) 2011-10-14
ES2535813T3 (es) 2015-05-18
KR20060006937A (ko) 2006-01-20
EP1623997B1 (en) 2015-04-22
AU2004232391A1 (en) 2004-11-04
NZ543345A (en) 2009-09-25
GEP20084476B (en) 2008-09-10
PE20050422A1 (es) 2005-06-29
RS51853B (en) 2012-02-29
CN1809592A (zh) 2006-07-26
AR044076A1 (es) 2005-08-24
TW200504090A (en) 2005-02-01
CL2004000843A1 (es) 2005-04-15
AU2004232391B2 (en) 2008-10-30
HK1183492A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
UY28289A1 (es) Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 y su uso para diasnostico y tratamiento de tumores
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
MX2020003888A (es) Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
MX2020004741A (es) Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos.
AR108663A1 (es) ANTICUERPOS CONTRA a-SINUCLEÍNA Y SUS USOS
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
ATE532795T1 (de) Tumor-assoziiertes peptid, welches an unterschiedliche menschliche leukozytenantigene der klasse ii bindet
PE20081625A1 (es) Proteinas de union al antigeno del receptor a de la il-17
AR071304A1 (es) Anticuerpos anti cd151 (proteina de membrana de la flia. de las tetraspaninas) utiles para el tratamiento de cancer
ECSP099379A (es) Anticuerpos anti-factor d humanizados
AR098256A1 (es) Vectores para expresión de antígenos asociados a próstata
AR066987A1 (es) Anticuerpo monoclonal contra proteina beta-amiloide
CR11374A (es) Proteinas humanas de union a antigenos del gm-csf
AR046068A1 (es) Anticuerpos de factor tisular y uso de los mismos
AR076668A1 (es) Anticuerpos especificos para dkk-1 y sus usos
CL2015001902A1 (es) Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina (divisional).
AR035539A1 (es) Moleculas de enlace capaces de enlazarse a isoformas cd45, polinucleotidos codificantes, un vector de expresion, un sistema de expresion, una celula huesped, el uso de dichas moleculas para la produccion de un medicamento y composiciones farmaceuticas.
CO2022001195A2 (es) Anticuerpos dirigidos contra dll3 y usos de los mismos
MX2020010701A (es) Péptidos antigénicos para la prevención y el tratamiento del cáncer.
BR112022009100A2 (pt) Peptídeos antigênicos para prevenção e tratamento de malignidade de células b
WO2020076969A3 (en) Anti-lap antibody variants and uses thereof
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
UY37630A (es) Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer
NZ750948A (en) Anti-gp73 antibodies and immunoconjugates
ECSP056112A (es) Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160621